Adamis Gets Another CRL For Opioid Overdose-Reversal Drug
Executive Summary
Adamis got its second complete response letter for Zimhi. While not apparently related to the first, it may complicate the company's outlook following a lackluster quarter.
You may also be interested in...
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Complete Response Letters
Details of action letters issued by US FDA, regularly updated with new announcements.
Ocuphire Chalks Up Another Phase III Success For Nyxol
The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.